NCT06431256: An ongoing trial by Ironshore Pharmaceuticals and Development, Inc
This trial is ongoing. It must report results 6 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06431256 |
|---|---|
| Title | Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and PK Study of Evening Dosed Methylphenidate Hydrochloride ER Capsules (HLD200) in Children Aged 4-5 Years With ADHD |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 13, 2024 |
| Completion date | July 11, 2025 |
| Required reporting date | July 11, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |